JNJ JOHNSON & JOHNSON
2026Q1 · CUSIP 478160104 · Big Pharma · Sector: Healthcare & Biotech
Lit · Institutions accelerating in
Holders
4,609
Δ holders QoQ
+89
Breadth percentile
Top 2%
Whale holders
368
Δ whales
-5
Inst. holding value
$416.4B
New positions
301
Closed positions
212
Price momentum (1Q)
-5.4%
Put / Call
55/49
Breadth history (34 quarters)
Past Lit Events & Aftermath 17 lit events
| Period | Percentile | Next-1Q return | Next-2Q return |
|---|---|---|---|
| 2026Q1 | Top 2% | — | — |
| 2025Q4 | Top 0% | -5.4% | — |
| 2025Q3 | Top 1% | +24.5% | +16.2% |
| 2025Q1 | Top 4% | +17.6% | +33.0% |
| 2024Q4 | Top 1% | -1.6% | +15.7% |
| 2024Q3 | Top 1% | +6.6% | +0.2% |
| 2023Q4 | Top 1% | -1.2% | +2.8% |
| 2023Q2 | Top 16% | -13.7% | -7.0% |
Options Sentiment
Put holders
55
QoQ: +5
Call holders
49
QoQ: -2
See methodology →
Fundamentals
PE (TTM)
29.3
EPS (TTM)
$8.63
EPS YoY
-4.0%
Revenue (TTM)
$96.4B
Revenue YoY
+7.9%
Quarterly Revenue & EPS (4Y)
Quarterly figures; EPS split-adjusted, early quarters hidden when not calibrable
P/E (TTM) over time
P/E = close 47 days after quarter-end (filing date) ÷ TTM EPS then; loss quarters hidden
As of 2026-03-29 · SEC filings (XBRL)